



CROSSING S.R.L.

One line pitch:

New active agents by Crossing for Sustainable Manufacturing of non-toxic skin, packaging, antimicrobial cellulose, active paints.



Market Analysis:

The Market of Crossing is related to a specific class of molecules used as activating agents of "cross-linking" (ACL), Crossing intends to develop the know-how needed for the production and industrial applications of innovative organic compounds such as ACL. Actually on the market only one ACL is known and his poor availability and very high costs drastically limit the use. Crossing arises in this segment of the market as a producer of an whole class of ACL. The current state of the world market for the production of ACL sees multinational and chinese companies as main suppliers, with prices up to EUR 1000 per kg, Crossing will sell whole classes of ACLs with price under Eur 40 per kg.

Value proposition:

Value proposition is based on assumptions that Crossing will be able to sell ACLs at 60-100 € and will be able to generates gains from research services for Clients using ACLs. Clients may be in the manufactory sector of leather, packaging, innovative fabrics or paints, dyes, new generation perfumes etc. Just considering the leather industry, supposing to reach 2% of European citizens, there will be available over 10 million beneficiaries of ACL technology customers, without considering that,by encouraging both by the EU and the citizens themselves, the markets push towards the development of processes and eco-friendly products for the reduction of hazardous materials and wastes.

Business Model:

The model is divided into three phases: - Development of molecules (already completed) - Development of application protocols - Transition to mass production The second phase is actually funded by customers that support the mass production of ACL and the method of application of the product. So, it will pass gradually from performance of services for the production for the Customer to the production related to the manufacture of a range of ACLs, to finally reach the production in a single plant, in collaboration with an industrial partner, with relatively small and quickly equipped batches, so to make low the cost of set up between one molecule and another.

IP and Regulatory situation:

The idea of ?Crossing is to use ACL for many manufacturing sectors using methodologies and ACL as now practiced in the pharmaceutical field. The charm of this business idea stems largely from the enormous possibilities of the application for ACL as activators in most part of the source compounds both synthetic and natural. Crossing has demonstrated the possibility of using the ACL for the production of low environmental impact of high quality leather. The wide availability of ACL, both in quantity and variety, will be a major boost to bring the level of industrialization in many applications, today known but not exploited due of the high cost and low availability of ACL.

COMPANY PROFILE

- **Website:**
<http://crossing-srl.com/>
- **Field:**
- **Contact:**
BEGHETTO Valentina
beghetto@unive.it
- **Location:**
Via Torino 155,
30172 Venice
Italy
- **Founded in:** //16/10/2014
- **Employees:** 0
- **Financial information (€):**
 - **Company stage:**
Commercial availability
 - **Capital raised to date:**
70.000
 - **Monthly burn rate:**
10.000
 - **Capital seeking and date:**
- **Investors:**